A case of denosumab-associated hyperparathyroidism: A differential diagnostic challenge
<p>Denosumab is a relatively new medicine that has become the second option in the treatment of biphosphonate-resistant or intolerant osteoporosis. Subcutaneous injection with 6-month intervals, approval of its usage in stage 3-4 CKD and not having gastrointestinal side effects are advantages...
Salvato in:
| Autori principali: | , , , , |
|---|---|
| Natura: | Libro |
| Pubblicazione: |
International Journal of Immunotherapy and Cancer Research - Peertechz Publications,
2021-10-08.
|
| Soggetti: | |
| Accesso online: | Connect to this object online. |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | peertech__10_17352_2455-8591_000033 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Emin Taşkıran |e author |
| 700 | 1 | 0 | |a Sevnaz Şahin |e author |
| 700 | 1 | 0 | |a Sumru Savaş |e author |
| 700 | 1 | 0 | |a Zeliha Fulden Saraç |e author |
| 700 | 1 | 0 | |a Selahattin Fehmi Akçiçek |e author |
| 245 | 0 | 0 | |a A case of denosumab-associated hyperparathyroidism: A differential diagnostic challenge |
| 260 | |b International Journal of Immunotherapy and Cancer Research - Peertechz Publications, |c 2021-10-08. | ||
| 520 | |a <p>Denosumab is a relatively new medicine that has become the second option in the treatment of biphosphonate-resistant or intolerant osteoporosis. Subcutaneous injection with 6-month intervals, approval of its usage in stage 3-4 CKD and not having gastrointestinal side effects are advantages of denosumab. However, it has some disadvantages like requiring monitoring serum levels of calcium and vitamin D before each injection. </p> | ||
| 540 | |a Copyright © Emin Taşkıran et al. | ||
| 546 | |a en | ||
| 655 | 7 | |a Case Report |2 local | |
| 856 | 4 | 1 | |u https://doi.org/10.17352/2455-8591.000033 |z Connect to this object online. |